Introduction
Twenty years after its first description, the transmembrane immunoglobulin-family member CD83 (1) is still an enigmatic molecule. It is a characteristic marker of mature dendritic cells (DCs) although its role on these cells is still unclear. The expression of CD83 on thymic epithelial cells is for unknown reasons essential for CD4 + T cell development (1). On B lymphocytes, CD83 is rapidly up-regulated within hours after stimulation in vitro and upon immunization in vivo (2, 3) and has been shown to function as a negative regulator of activation, maturation and homoeostasis (1) . CD83 transgenic (CD83tg) mice produce drastically reduced amounts of immunoglobulin upon immunization with T cell-dependent and T cell-independent (TI)-2 model antigens (2) . Vice versa, B cells from CD83 mutant mice that lack functional CD83 secrete slightly enhanced amounts of immunoglobulin and, thus, show a reciprocal phenotype (4) . The inhibitory effect of CD83 is due to CD83 over-expression on the B cells themselves (1) . Purified CD83tg B cells show reduced calcium influx and reduced proliferation compared with wild type (Wt) B cells upon BCR stimulation in vitro (4) . Finally, the application of a CD83-specific antibody enhances immunoglobulin production in response to immunization with TI model antigen (5) . This can be explained by the interference of the antibody with the interaction of CD83 with its natural yet unknown ligand(s). Because CD83 does not contain any known signaling motifs in its short intracellular domain, CD83 must mediate its effects via the interaction with other signaling molecules. The mechanisms underlying CD83-mediated B cell inhibition, however, are still obscure.
Nevertheless, CD83tg B cells are not generally defective but react to TLR engagement with enhanced production of IL-10, whereas CD83 mutant B cells secrete reciprocally reduced amounts of this cytokine (4) . This study was conducted to further dissect the influence of CD83 on the response of different B cell subsets to stimulation via the BCR or TLRs.
We show that in response to stimulation via the BCR, CD83tg B cells show strongly reduced numbers of proliferating cells among all B cell subsets. Detectable amounts of IL-10 are produced by neither CD83tg nor Wt B cells in response to BCR stimulation. Interestingly, follicular (FO) but not marginal zone (MZ) or transitional (TN) B cells from CD83tg mice undergo enhanced apoptosis. Analysis of BCR-mediated signaling events revealed that the presence of CD83 interferes with the phosphorylation of LYN and SYK. Thus, CD83 already inhibits the initiation of BCR-mediated signaling, which further leads to reduced downstream activation of ERK1/2.
In contrast, in response to LPS, all CD83tg B cell subsets show normal frequencies of proliferating cells although TLR4 engagement is not able to rescue CD83tg FO B cells from apoptosis. CD83tg B cells produce enhanced amounts of IL-10 in response to LPS, for which MZ B cells are responsible. CD83tg MZ B cells, but not FO B cells, react to TLR4 engagement with enhanced ERK1/2 activation, which is partially responsible for the increased IL-10 release. Finally, we show that MZ B cells in contrast to FO and TN B cells express almost maximum levels of CD83 already 2 h after LPS stimulation.
These observations together with the finding that CD83 co-localizes with the BCR suggest that CD83 already inhibits BCR-mediated signal initiation leading to insufficient activation of all B cell subsets and reduced survival especially of FO B cells. On the other hand, CD83 also associates with the LPS receptor complex and enhances TLR4-mediated IL-10 release exclusively in MZ B cells. Thus, CD83 differentially regulates MZ and FO B cell responses by modulating TLR and BCR signaling.
Methods

Mice
CD83tg C57BL/6 mice (CD83tg), C57BL/6 Wt and IL-10/ EGFP reporter mice were maintained in the animal facilities of the Bernhard Nocht Institute for Tropical Medicine (Hamburg, Germany) that are registered by the public health authority in charge (Behoerde für Gesundheit und Verbraucherschutz, Food and Veterinary Office, Hamburg, Germany). IL-10/EGFP reporter mice were generated by Dr Matthias Haury and Dr Dinis Calado at the Instituto Gulbenkian de Ciência, Oeiras, Portugal. These mice carry the EGFP-encoding cDNA integrated into the IL-10 locus 3ʹ of the last IL-10 exon. EGFP expression in these mice is coupled to IL-10 expression by an IRES sequence and controlled by the IL-10 promoter. IL-10/EGFP reporter mice were bred to Wt and CD83tg mice.
The study does not contain animal experimentation and is exempt from obtaining approval under the conditions stipulated in section 8 of the Animal Welfare Act.
Antibodies and reagents
Rat anti-mouse CD83 (Michel-19) was generated at the Bernhard Nocht Institute for Tropical Medicine and labeled with FITC, Alexa488 or Alexa647 employing the labeling kits from Molecular Probes/Invitrogen (Leiden, Netherlands). Biotinylation of the antibody was performed with the biotinylation kit from ThermoScientific (Bonn, Germany). Rat anti-mouse CD21-PE (7G6), allophycocyanin-and FITC-labeled rat anti-mouse CD19 (clone 1D3), rat antimouse Ig κ light chain (clone 187.1), hamster anti-mouse CD40 (clone HM40-3) and rat anti-mouse CD45-FITC (clone 30-F11) were obtained from BD Biosciences (Heidelberg, Germany).
Rat anti-mouse CD23-allophycocyanin (clone B3B4) was purchased from Invitrogen (Karlsruhe, Germany). Rat anti-mouse CD1d-PE (clone 1B1) and annexin V-PE/7-AAD staining kit were obtained from eBioscience (Frankfurt, Germany). Rabbit anti-FITC-Alexa488 was provided by Caltag Laboratories, Buckingham, UK. Rabbit anti-mouse phospho-ERK1/2 (Thr202/Tyr204; clone DE13.14.4E), rabbit anti-mouse ERK1/2 (clone 137F5), rabbit anti-phospho-LYN (Tyr507), rabbit anti-phosphoSrc family (Tyr416), rabbit anti-LYN (clone C13F9), rabbit anti-phospho-SYK (Tyr525/526; clone C87C1), rabbit anti-SYK and U0126 (MEK1/2 inhibitor) were purchased from Cell Signaling Technology/New England Biolabs (Frankfurt am Main, Germany). Goat anti-rabbit-HRP was obtained from DAKO (Glastrup, Denmark). LPS from Escherichia coli (strain 055:B5) and 4,6-diamidin-2-phenylindol (DAPI) were obtained from Sigma-Aldrich (Steinheim, Germany). LPSAlexa488 from E. coli strain 055:B5 and CFSE were purchased from Molecular Probes/Invitrogen. Biotinylated LPS from E. coli (strain 0111:B4) was obtained from InvivoGen (San Diego, CA, USA). Streptavidin-TRITC as well as FITClabeled and biotinylated donkey anti-mouse IgM (μ chain specific) were purchased from Jackson ImmunoResearch (Newmarket, Suffolk, UK).
B cell purification and stimulation
B cells were purified from the spleen of mice by negative selection employing the B cell purification kits from Miltenyi Biotec (Bergisch-Gladbach, Germany) or StemCell Technology (Grenoble, France). Generally, these cell preparations contained >95% CD19 + B cells. FO and the MZ/ TN B cell fractions were further separated by staining with biotinylated anti-CD23 and positive selection of CD23 + FO and negative selection of CD23 − MZ+TN B cells with magnetic anti-biotin beads (Miltenyi Biotec). MZ B cells were further separated by staining with anti-CD21-PE and magnetic anti-PE beads (Miltenyi Biotec). Cells were cultured in RPMI1640 supplemented with 10% FCS, 4 mM glutamine, 20 mM HEPES, 50 μg/ml gentamycin from PAA (Linz, Austria) and 50 μM mercaptoethanol (Sigma, Deisenhofen, Germany). To measure proliferation and cytokine production, 2 × 10 5 purified total B cells, FO or MZ/TN B cells were stimulated with 10 μg/ml LPS from E. coli (strain 055: B5) or a combination of 2 μg/ml anti-mouse Ig κ light chain and 2 μg/ml anti-mouse CD40 in 96-well round-bottom plates for 24, 48 or 72 h. Supernatants were analyzed for the presence of IL-10 by specific ELISA (R&D Systems, Wiesbaden, Germany). Proliferation was measured by 3 H thymidine (10 μCi/ml; GE Healthcare, Munich, Germany) incorporation. 48 h after stimulation, 3 H thymidine was added to the cells to a final concentration of 1.25 μCi/ml. Cells were incubated for 18 h and harvested and transferred to a glass fiber filter. The filter was dried, shrinkwrapped with β scintillation solution and measured in a β scintillator.
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CFSE labeling
For CFSE labeling, 1 × 10 7 purified B cells were re-suspended in PBS/3% FCS and 200 μl of a 50 μM CFSE (Invitrogen, Karlsruhe, Germany) solution was added. Cells were mixed and incubated for 10 min at 37°C in the dark. Afterwards, cells were washed three times with 30 ml cold PBS/3% FCS. Cells were finally re-suspended in cell culture medium. Labeling was controlled by flow cytometric analysis.
Western blot detection of LYN, SYK and ERK1/2
For western blot detection of LYN, SYK and ERK1/2, 5 × 10 6 total B cells or separated FO and MZ+TN B cells were washed in serum-free RPMI1640 culture medium and stimulated either with 10 μg/ml LPS or 2 μg/ml anti-mouse Ig κ light in 200 μl serum-free RPMI1640 culture medium for the indicated time points. Cells were lysed in lysis buffer (150 mM NaCl, 20 mM Tris, 1% Triton-X100, protease inhibitor cocktail, pH 7.2). Cell lysates were applied to SDS-PAGE and semi-dry western blotting onto Hybond ECL nitrocellulose membrane (GE Healthcare, Freiburg, Germany). Membranes were blocked with 4% milk powder in Tris-buffered saline (TBS; 150 mM NaCl, 50 mM Tris-HCl, pH 7.6) with 0.1% Tween 20 and washed in TBS/0.1% Tween 20. Then, membranes were incubated with rabbit anti-mouse phospho-ERK1/2 (Thr202/ Tyr204; 1:1000), rabbit anti-phospho-LYN (Tyr507; 1:1000), rabbit anti-phospho-Src family (Tyr416; corresponding to Tyr397 of the murine LYN kinase; 1:1000) or rabbit antiphospho-SYK (Tyr525/526; 1:1000) in TBS/5% BSA/0.1% Tween 20 overnight at 4°C followed by washing and incubation with anti-rabbit-HRP (1:2000 in TBS/0.1%. Tween 20/4% milk powder) for 1 h. After detection, the membranes were stripped in stripping buffer (ThermoScientific), blocked with 4% milk powder again and developed with rabbit anti-mouse ERK1/2 (1:2000), rabbit anti-LYN (1:1000) or rabbit anti-SYK (1:1000) and anti-rabbit-HRP in a similar fashion. Detection was performed with ECL reagent (Thermo Fisher Scientific, Bonn, Germany) on a Fusion SL4 gel documentation system (Vilber Lourmat, Eberhardzell, Germany). Quantification was performed with ImageJ software (National Institutes of Health, Bethesda, MD, USA).
Flow cytometry
For flow cytometric analysis, 5 × 10 5 -1 × 10 6 cells were used. RAW264.7 macrophages were cultured in chamber slides and stimulated with 10 μg/ml LPS for 4 h to induce up-regulation of CD83. Fc receptors were blocked in PBS with 5% mouse serum. For cross-linking of the LPS receptor complex, cells were then incubated with biotinylated LPS (10 μg/ml) in PBS/5% mouse serum for 15 min at 37°C followed by washing with PBS and incubation with streptavidin-TRITC (1:1000) for an additional 15 min at 37°C. Control cells were stained in the same fashion on ice. After washing, cells were stained with anti-CD83-Alexa488 (1:100) and DAPI (1:1000) on ice. Finally, cells were washed, fixed in PBS/1% PFA and covered with permafluor medium. CD83tg spleen cells were stained in solution and centrifuged onto glass slides afterwards. Control cells were stained with streptavidin-TRITC in the absence of biotinylated LPS. Cells were analyzed with an Axioskop 2 plus microscope (Carl Zeiss GmbH, Jena, Germany) employing OpenLab 5.0.1 software (Improvision, Coventry, UK).
Cytokine detection
IL-10 was detected employing the DuoSet IL-10 ELISA kit from R&D Systems according to the manufacturer's protocol.
Results
Differential response of CD83tg B cells to BCR and TLR stimulation
Constitutive expression of CD83 in B cells has been described to lead to reduced proliferation but enhanced IL-10 production in response to LPS stimulation (4). We now compared proliferation and IL-10 production in response to BCR and TLR4 engagement. Purified splenic B cells from Wt and CD83tg mice were stimulated either via the BCR by addition of a combination of anti-mouse Ig κ and anti-mouse CD40 antibodies or via the TLR4 with LPS.
When stimulated via the BCR, CD83tg B cells showed strongly reduced 3 H thymidine incorporation compared with Wt B cells (Fig. 1A) although they expressed normal levels of surface IgM (Fig. 1B) . Obviously, the reduced response of CD83tg B cells to BCR engagement was not due to altered expression of the IgM BCR. Neither CD83tg nor Wt B cells produced detectable amounts of IL-10 when stimulated via the BCR. In contrast, stimulation with LPS resulted in a high proliferative response of CD83tg B cells (although still significantly lower than in Wt B cells) and the secretion of large amounts of IL-10 that were significantly higher than in 
Regulation of BCR and TLR4 signaling by CD83 511
Wt B cells (Fig. 1C) . To investigate the expression of the LPS receptor complex on different B cells, we used cell surface binding of LPS-Alexa488 in flow cytometry and distinguished different B cell subsets from Wt and CD83tg mice by staining CD1d and CD23 as described in the literature (6) (7) (8) (9) . Both markers were stably expressed on naive and stimulated B cells (Supplementary Figure S1 , available at International Immunology Online). Figure 1D . Among naive cells, only MZ B cells bound LPS-Alexa488, whereas all B cell subsets bound LPS-Alexa488 after stimulation. Thus, LPS stimulation induced up-regulation of the LPS receptor complex in all B cell subsets. Similar up-regulation of TLR4 expression by LPS has been described for other immune cells, for example macrophages, and is most likely ascribed to LPS-induced IL-6 production (10). This cytokine is also produced by B cells upon LPS stimulation (11) , which may explain enhanced LPS receptor expression on activated B cells. Both, Wt and CD83tg B cells, bound comparable amounts of LPS-Alexa488 (Fig. 1E ) demonstrating that CD83tg B cells express normal levels of the LPS-binding TLR4 receptor complex. Altered expression of the latter is, therefore, not responsible for enhanced IL-10 release by CD83tg B cells in response to LPS.
To further assess the proliferative response of Wt and CD83tg B cell subsets, we labeled purified B cells with CFSE prior to stimulation and analyzed the frequency of proliferating CFSE low cells by flow cytometry. CD83tg B cells showed a significantly reduced percentage of proliferating cells upon BCR activation (Fig. 2A, top and middle panels). Reduced proliferation was observed in all B cell subpopulations ( Fig. 2A, bottom panel) . To our surprise, frequencies of proliferating CD83tg B cells were unaltered compared with Wt B cells when cells were stimulated with LPS (Fig. 2B, top and middle panels) . This was true for all B cell subpopulations (Fig. 2B, bottom panel) . These results were confirmed by additional experiments employing 7-AAD to exclude apoptotic cells (Supplementary Figure S2 , available at International Immunology Online) and demonstrate that all CD83tg B cell subsets proliferate normally upon TLR4 engagement and only react to BCR stimulation with reduced proliferation.
Reduced survival of CD83tg FO B cells
As CD83tg B cells showed normal frequencies of proliferating cells upon LPS stimulation, reduced thymidine incorporation by CD83tg B cells in response to LPS (Fig. 1) (Fig. 3A) , thereby enhanced amounts of dead CD83tg FO B cells were already visible among freshly prepared naive B cells (Fig. 3A) . The frequency of both, apoptotic Wt and CD83tg FO B cells, increased upon stimulation via TLR4 or the BCR. However, the percentage of apoptotic CD83tg FO B cells was still significantly enhanced compared with Wt FO B cells (Fig. 3A) . In contrast, normal frequencies of apoptotic cells were observed among naive and LPS-or BCR-stimulated CD23 − MZ and TN B cells (Fig. 3B) . These results show that CD83 over-expression leads to reduced survival exclusively of FO B cells, whereas MZ and TN B cells are not affected.
CD83 interferes with BCR signal initiation and ERK1/2 activation
It has been shown that CD83tg B cells react to BCR engagement with reduced calcium influx (4). We next addressed the question whether CD83 modulates intracellular BCR-or TLRmediated signal transduction. The first events that take place upon BCR engagement are the phosphorylation and activation of Src kinases such as LYN, FYN and BLK and subsequent activation of the tyrosine kinase SYK (12) . We, therefore, analyzed the phosphorylation of the kinases LYN and SYK in Wt and CD83tg B cells by western blotting after stimulation via the BCR. The two independent experiments depicted in Fig. 4A show that phosphorylation of Tyr507 of the LYN kinase was dramatically reduced or almost absent in CD83tg B cells compared with Wt B cells that showed a clear induction of LYN phosphorylation after 1-3 min (Fig. 4A) . In addition, phosphorylation of LYN Tyr396 and SYK Tyr525/526 was delayed and reduced in CD83tg B cells compared with Wt B cells (Fig. 4A) . We further analyzed the activation of the MAP kinase ERK1/2 as a distal signaling event that delivers important proliferative and survival signals (13) (14) (15) (16) (17) . We found that phosphorylation of ERK1/2 upon BCR engagement was strongly reduced in CD83tg B cells (Fig. 4B) . These results show that CD83 interferes already with the initiation of the BCR-mediated signaling leading to reduced ERK1/2 activation.
CD83 enhances TLR4-mediated ERK1/2 activation, which is partially responsible for IL-10 induction
Apart from delivering survival signals upon BCR stimulation, the activation of ERK1/2 has been shown to be crucial for the production of IL-10 in antigen-presenting cells such as macrophages and DCs upon TLR ligation (18) (19) (20) . In addition, the activation of ERK1/2 is required to deliver survival signals in B cells during mitogenic stimulation (21-23). We, therefore, analyzed the activation of this MAPK in response to LPS. We observed that CD83tg B cells react to LPS with enhanced ERK1/2 phosphorylation (Fig. 5A) . To further investigate the role of ERK1/2 in the induction of IL-10 in CD83tg B cells, we made use of the inhibitor U0126 that selectively inhibits the ERK1/2 kinase MEK (24) (25) (26) (27) . The addition of U0126 completely abolished the phosphorylation of ERK1/2 in response to LPS in Wt and CD83tg B cells (Fig. 5A) . Next, we stimulated B cells from Wt and CD83tg mice with LPS in the presence of U0126 for 48 h to measure 3 H thymidine incorporation and IL-10 content in the supernatants. MEK inhibition did not alter B cell proliferation but significantly reduced IL-10 production by both, Wt and CD83tg B cells (Fig. 5B) . Inhibition of ERK1/2, however, did not completely abrogate IL-10 release and CD83tg B cells still produced significantly higher amounts of IL-10 compared with Wt B cells (Fig. 5B) .
These results show that the activation of ERK1/2 is necessary but not solely responsible for the induction of IL-10 in B cells in response to LPS as it has been demonstrated for other antigen-presenting cells such as macrophages and DCs (18) (19) (20) and that enhanced ERK1/2 activation contributes to increased IL-10 production by CD83tg B cells.
Enhanced ERK1/2 activation is restricted to CD83tg MZ B cells
We next investigated the influence of CD83 over-expression on ERK1/2 activation in different B cell subsets. To this end, we purified CD23 + FO B cells with magnetic beads and further isolated CD21 + MZ B cells from the CD23 − fraction. Isolated FO and MZ B cells from Wt and CD83tg B cells were then stimulated with LPS and phosphorylated ERK1/2 was detected in western blots of cell lysates. CD83tg MZ B cells reacted to LPS stimulation with enhanced ERK1/2 activation compared with Wt MZ B cells. An increase of ERK1/2 phosphorylation was visible within 30 min after addition of LPS and further increased until 60 min after stimulation (Fig. 6A) . In FO B cells, ERK1/2 phosphorylation was generally weaker. In contrast to MZ B cells, CD83tg FO B cells did not show enhanced ERK1/2 activation upon TLR4 engagement Regulation of BCR and TLR4 signaling by CD83 513 ( Fig. 6B ). These results demonstrate that over-expression of CD83 promotes ERK1/2 activation in response to LPS exclusively in MZ B cells.
CD83 over-expression selectively enhances IL-10 release by MZ B cells in response to LPS
To further analyze the nature of the IL-10-producing B cell fraction, we made use of an IL-10/EGFP reporter mouse. We crossed these mice to CD83tg mice and generated CD83tg mice that express EGFP controlled by the IL-10 promoter (Fig. 7A) . As a control, we crossed Wt mice to the IL-10/EGFP reporter mice. Purified B cells from these mice were stimulated with LPS and EGFP-expressing cells were detected by flow cytometry. Figure 7B shows an example of this measurement whereby FO, MZ and TN B cells were distinguished by staining of CD1d and CD23 as described previously. Both, MZ and TN B cells, produced IL-10 in response to LPS, whereas only low amounts of IL-10-expressing FO B cells were observed (Fig. 7B and C) . Clearly, over-expression of CD83 selectively enhanced IL-10 expression in MZ B cells (Fig. 7B and C) .
We next addressed the question whether CD83 is differentially up-regulated on the different B cell subsets upon stimulation. Therefore, we analyzed the kinetics of CD83 expression on B cell subpopulations from Wt mice upon stimulation with LPS and distinguished FO, MZ and TN B cells by staining of CD23 and CD1d as shown previously. Figure 7D shows that, even among naive cells, MZ B cells express significantly higher levels of CD83 compared with FO and TN B cells. Upon LPS stimulation, CD83 was most quickly up-regulated on MZ B cells and reached almost maximum expression 2 h after stimulation. Compared with MZ B cells, up-regulation of CD83 on FO B cells was significantly delayed. Although enhanced expression of CD83 on FO B cells was also detectable 2 h after stimulation, maximum levels of CD83 expression on FO B cells were reached after 24 h. At this time point, MZ and FO B cells expressed comparable levels of CD83 (Fig. 7D) . Immature TN B cells up-regulated CD83 with similar kinetics as FO B cells but generally expressed significantly lower amounts of CD83 at all time points (Fig. 7D) . These results show that naturally expressed CD83 is most quickly up-regulated on MZ B cells in response to LPS. 6 purified B cells from Wt or CD83tg mice were stimulated with 2 μg/ml anti-Ig κ for indicated time points. Cell lysates were applied to western blotting. Phosphorylated LYN (Tyr396 and Tyr507) and SYK (Tyr525/526) were detected, and total LYN and SYK were detected after stripping of the membranes. The figure shows two independent experiments (experiment 1 and experiment 2) (A). B cells were stimulated as described above. Phosphorylated ERK1/2 was detected on western blots of cell lysates and total ERK1/2 was detected on the same membrane after stripping. The western blot is representative of three independent experiments. The graph shows the mean and SEM of the ratio of phosphorylated pERK1/2:ERK1/2 (y-axis) of three independent experiments (B).
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CD83 co-localizes with both the IgM BCR and the LPS receptor complex
The data presented thus far show that CD83 is involved in the regulation of BCR and TLR4 signaling. Because CD83 does not contain any known signaling motifs in its short intracellular domain, the molecule must interact with other signaling molecules to mediate its immunomodulatory effects. According to this hypothesis, we analyzed whether CD83 co-localizes with the BCR complex and/or with the LPS receptor complex. First, we cross-linked CD83 on the surface of naive CD83tg B cells or LPS-activated Wt B cells that up-regulated CD83 and counterstained the cells with IgM-specific antibody. Cross-linking of CD83 led to coaccumulation of the IgM BCR in CD83-enriched regions on CD83tg B cells (Fig. 8A ) and on stimulated Wt B cells that expressed natural activation-induced CD83 (Fig. 8B) . Next, we analyzed whether CD83 would also co-localize with the LPS binding receptor complex. For the first experiments, RAW264.7 macrophages instead of B cells were used as these express higher amounts of TLR4. LPS-stimulated RAW264.7 cells up-regulated CD83 within 4 h (data not shown). At this time point, the cells were incubated with biotinylated LPS followed by streptavidin-TRITC to induce a cross-linking of the LPS receptor complex. Afterwards, CD83 was stained. Figure 9A shows that large amounts of CD83 co-localized with LPS-binding sites in several spots on RAW264.7 cells. Control macrophages that were treated in a similar manner but incubated on ice did not show aggregation of the LPS receptor complex and only partial co-localization with CD83 (Fig. 9B) . In a second approach, spleen cells from CD83tg mice were used and treated in a similar fashion but in solution followed by cytospin. Here, co-aggregation of CD83 with LPS-binding spots was observed on several cells (Fig. 9C) . Staining of control cells with streptavidin-TRITC in the absence of biotinylated LPS showed negligible background staining (Fig. 9D) demonstrating specific binding of this reagent to membranebound biotinylated LPS.
These results demonstrate that CD83 indeed co-localizes with the BCR and the LPS receptor complex suggesting that CD83 interacts with components of each of these complexes.
Discussion
In this study, we analyzed the influence of CD83 on the response of B cell subpopulations to BCR and TLR4 engagement. We show that CD83 regulates major signal transduction pathways downstream of the BCR and TLR4 and in this way differentially regulates FO and MZ B cell responses. 6 purified B cells from Wt or CD83tg mice were stimulated with 10 μg/ml LPS in the presence of dimethyl sulfoxide (DMSO) as a control or U0126 for the indicated time points. Phosphorylated ERK1/2 was detected on western blots of cell lysates. Total ERK1/2 was detected on the same membrane after stripping. The western blot is representative of two independent experiments (A). 2 × 10 5 purified B cells from Wt or CD83tg mice were stimulated with 10 μg/ml LPS in the presence of DMSO as a control or U0126. Supernatants were analyzed for IL-10 content (y-axis, B left) and Analyzing BCR-induced intracellular signaling events, we show that CD83 interferes with the activation of LYN and SYK and, thus, already with the initiation of BCR-mediated signaling (28) (29) (30) . Consequently, this leads to reduced calcium influx (4) and activation of ERK1/2, which is one of the most important signaling pathways regulated by SYK (31) . The activation of the MEK/ERK1/2 pathway is required for the delivery of proliferative and survival signals. Upon BCR stimulation, ERK1/2 activates the transcription factors SRF (serum response factor), NFAT (nuclear factor of activated T cells) and AP-1 (activator protein 1) that are involved in the regulation of cell growth and differentiation (13) (14) (15) (16) . All CD83tg B cell subsets reacted to stimulation via the BCR and CD40 with reduced proliferation. We interpret these data as a result of inhibition of BCR-mediated activation of ERK1/2 (and other factors) by CD83 although a potential influence of CD83 also on CD40 signaling cannot be excluded in this experimental setup.
In addition, ERK1/2 kinases exert anti-apoptotic functions (17) . We observed that exclusively FO B cells from 6 purified MZ (A) and FO (B) B cells from Wt or CD83tg mice were stimulated with 10 μg/ml LPS for the indicated time points. Phosphorylated ERK1/2 was detected on western blots of cell lysates. Total ERK1/2 was detected on the same membrane after stripping. Graphs show the mean and SEM of the ratio of phosphorylated ERK1/2:ERK1/2 of three independent experiments (y-axis).
effects in antigen-presenting cells and is required for B cell (and also T cell) survival during mitogenic stimulation (21) (22) (23) . Analyzing the activation of purified splenic MZ and FO B cells by LPS, we found that CD83tg MZ B cells but not FO B cells showed enhanced ERK1/2 activation in response to LPS. Thus, LPS-induced ERK1/2 activation in FO B cells is too weak to counterbalance the CD83-mediated inhibition of BCR signaling leading to enhanced apoptosis.
Neither Wt nor CD83tg B cells produced detectable amounts of IL-10 in response to BCR engagement, whereas LPS stimulation led to significantly enhanced IL-10 release by CD83tg B cells (4) . Apart from its anti-apoptotic function, activation of ERK1/2 has been demonstrated to be essential although not solely responsible for the induction of IL-10 in antigen-presenting cells such as macrophages and DCs (18) (19) (20) . ERK1/2 phosphorylation could be completely suppressed by the addition of the specific MEK inhibitor U0126, which led to reduced IL-10 release by both, Wt and CD83tg B cells, upon LPS stimulation. IL-10 secretion, however, was not completely abrogated by U0126 and the inhibitor was not able to reduce IL-10 secretion by CD83tg B cells to Wt levels. These results not only demonstrate the importance of ERK1/2 activation for the induction of IL-10 in B cells but also show that other factors must be involved in enhanced induction of IL-10 expression in CD83tg B cells.
Employing Wt and CD83tg IL-10/EGFP reporter mice, we finally demonstrate that IL-10-producing cells were predominantly detectable among TN and MZ B cells in response to LPS. This is in line with the literature where it has been described that MZ, TN MZ precursor cells and B1 B cells are the dominant source of IL-10 in the spleen (42) (43) (44) . MZ and TN B cells from Wt mice showed comparable frequencies of IL-10-expressing cells. Among B cells from CD83tg mice, however, the frequency of IL-10-secreting cells was exclusively enhanced in the MZ B cell fraction compared with Wt B cells. Whether these cells show further characteristics of the newly described regulatory B cells (44) (45) (46) was not analyzed in this study and remains to be elucidated.
Interestingly, the effect of CD83 on TLR-mediated IL-10 release was not restricted to the B cell compartment. Apart from B cells, we also found enhanced IL-10 release by CD83tg DCs upon LPS stimulation. Furthermore, IL-12 production by LPS-stimulated CD83 over-expressing DCs was reciprocally reduced, whereas TNF-α release was unchanged (Supplementary Figure S3 , available at International Immunology Online). Here, similar mechanisms as observed for CD83tg B cells including the activation of ERK1/2 may be responsible for this effect. CD83tg DCs show the opposite phenotype than DCs from ERK1 knockout mice that produce reduced amounts of IL-10 and enhanced amounts of IL-12 upon TLR stimulation (47), the latter being most likely due to feedback inhibition of IL-12 expression by 48) .
How CD83 regulates BCR or TLR signaling, however, is still enigmatic. The short intracellular domain of CD83 does not possess any known intracellular signaling motifs. CD83 is, therefore, not able to transduce intracellular signals itself but must interact with other molecules. We show that CD83 co-localizes with the BCR and LPS-binding sites indicating that CD83 interacts with components of both, the BCR and TLR receptor complexes. The identity of CD83 interaction partners that are responsible for CD83-mediated signal modulation, however, remains to be elucidated.
On the basis of our findings, we hypothesize that during an ongoing immune reaction, CD83 functions as a general counter-regulator that dampens otherwise overwhelming immune responses. CD83 directly inhibits BCR signaling leading to insufficient activation signals and reduced survival of FO B cells. In this way, CD83 may contribute to the termination of B cell responses. On the other hand, CD83 enhances TLRmediated IL-10 production in MZ B cells, DCs and maybe other TLR-expressing cells and thereby counter-regulates inflammatory immune responses. Thus, CD83 differentially regulates MZ and FO B cell responses by modulating BCR and TLR signaling. 
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